Literature DB >> 18779606

Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.

Susan K Lutgendorf1, Aliza Z Weinrib, Frank Penedo, Daniel Russell, Koen DeGeest, Erin S Costanzo, Patrick J Henderson, Sandra E Sephton, Nicolas Rohleder, Joseph A Lucci, Steven Cole, Anil K Sood, David M Lubaroff.   

Abstract

PURPOSE: Inflammatory processes have been implicated in the pathogenesis of both depression and cancer. Links between depressive symptoms, interleukin-6 (IL-6), and cortisol dysregulation have been demonstrated in cancer patients, but vegetative versus affective components of depression have been minimally examined. The objective of the current study was to examine associations between IL-6, diurnal cortisol rhythms, and facets of depression in epithelial ovarian cancer patients. PATIENTS AND METHODS: Patients awaiting surgery for a pelvic mass suspected for ovarian cancer completed questionnaires, collected salivary samples for 3 days presurgery, and gave a presurgical blood sample. Ascites was obtained during surgery. IL-6 was measured by enzyme-linked immunosorbent assay and cortisol by a chemiluminescence immunoassay. The final sample included 112 invasive ovarian cancer patients (86 advanced stage, 26 early stage) and 25 patients with tumors of low malignant potential (LMP).
RESULTS: Advanced-stage ovarian cancer patients demonstrated elevations in vegetative and affective depressive symptoms, plasma IL-6, and the cortisol area under the curve (AUC) compared with patients with LMP tumors (all P < .05). Among invasive ovarian cancer patients, greater vegetative depression was related to elevated IL-6 in plasma (P = .008) and ascites (P = .024), but affective depression was unrelated to IL-6. Elevations in total depression (P = .026) and vegetative depression (P = .005) were also related to higher evening cortisol levels. Plasma IL-6 was related to greater afternoon and evening cortisol and cortisol AUC (all P values < .005).
CONCLUSION: These results demonstrate significant relationships between IL-6, cortisol, and vegetative depression, and may have implications for treatment of depression in ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779606      PMCID: PMC2653140          DOI: 10.1200/JCO.2007.14.1978

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  56 in total

1.  Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture.

Authors:  G P Chrousos
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

Review 2.  Salivary cortisol in psychobiological research: an overview.

Authors:  C Kirschbaum; D H Hellhammer
Journal:  Neuropsychobiology       Date:  1989       Impact factor: 2.328

3.  Serum evaluation of interleukin 6 in ovarian cancer patients.

Authors:  C Tempfer; H Zeisler; G Sliutz; G Haeusler; E Hanzal; C Kainz
Journal:  Gynecol Oncol       Date:  1997-07       Impact factor: 5.482

4.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.

Authors:  T B Harris; L Ferrucci; R P Tracy; M C Corti; S Wacholder; W H Ettinger; H Heimovitz; H J Cohen; R Wallace
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

5.  Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma.

Authors:  N H Obata; K Tamakoshi; K Shibata; F Kikkawa; Y Tomoda
Journal:  Anticancer Res       Date:  1997 Jan-Feb       Impact factor: 2.480

6.  Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls.

Authors:  M Deuschle; U Schweiger; B Weber; U Gotthardt; A Körner; J Schmider; H Standhardt; C H Lammers; I Heuser
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

Review 7.  Circadian-system alterations during cancer processes: a review.

Authors:  M C Mormont; F Lévi
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

8.  The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function.

Authors:  C M Pariante; B D Pearce; T L Pisell; C I Sanchez; C Po; C Su; A H Miller
Journal:  Endocrinology       Date:  1999-09       Impact factor: 4.736

9.  Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma.

Authors:  R A Burger; E A Grosen; G R Ioli; M E Van Eden; M Park; M L Berman; A Manetta; P J Disaia; G A Granger; T Gatanaga
Journal:  J Interferon Cytokine Res       Date:  1995-03       Impact factor: 2.607

10.  Association of interleukin-6 and other biologic variables with depression in older people living in the community.

Authors:  A N Dentino; C F Pieper; M K Rao; M S Currie; T Harris; D G Blazer; H J Cohen
Journal:  J Am Geriatr Soc       Date:  1999-01       Impact factor: 5.562

View more
  82 in total

1.  Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.

Authors:  Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

Review 2.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

Review 3.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

Review 4.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 5.  Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

Authors:  Julienne E Bower; Donald M Lamkin
Journal:  Brain Behav Immun       Date:  2012-07-06       Impact factor: 7.217

Review 6.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

7.  Social enrichment attenuates chemotherapy induced pro-inflammatory cytokine production and affective behavior via oxytocin signaling.

Authors:  William H Walker; O Hecmarie Meléndez-Fernández; Jordan L Pascoe; Ning Zhang; A Courtney DeVries
Journal:  Brain Behav Immun       Date:  2020-07-29       Impact factor: 7.217

Review 8.  Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.

Authors:  Christine D Craig; Bradley J Monk; John H Farley; Dana M Chase
Journal:  Support Care Cancer       Date:  2013-11-10       Impact factor: 3.603

9.  Effects of IL-6 and cortisol fluctuations in post-stroke depression.

Authors:  Xiao-Fan Zhang; Wei Zou; Yuan Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

10.  Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.

Authors:  Susan K Lutgendorf; George M Slavich; Koenraad Degeest; Michael Goodheart; David Bender; Premal H Thaker; Frank Penedo; Bridget Zimmerman; Joseph Lucci; Luis Mendez; Katherine Collins; Anil K Sood
Journal:  Gynecol Oncol       Date:  2013-10-03       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.